Detalhe da pesquisa
1.
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Haematologica;
109(4): 1149-1162, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37646671
2.
Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma.
Haematologica;
107(5): 1144-1152, 2022 05 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34289656
3.
The epichaperome is an integrated chaperome network that facilitates tumour survival.
Nature;
538(7625): 397-401, 2016 Oct 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27706135
4.
Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib.
Br J Haematol;
194(1): 83-91, 2021 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33942292
5.
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med;
378(12): 1107-1120, 2018 Mar 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29562156
6.
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.
Blood;
133(20): 2121-2129, 2019 05 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30770396
7.
A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL.
Blood;
131(16): 1805-1808, 2018 04 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29386196
8.
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
N Engl J Med;
374(4): 311-22, 2016 Jan 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26639348
9.
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.
Blood;
130(20): 2196-2203, 2017 11 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28874350
10.
In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-Fluoroglutamine.
Radiology;
287(2): 667-675, 2018 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29388903
11.
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.
Blood;
128(11): 1458-64, 2016 09 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27458003
12.
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.
Invest New Drugs;
35(6): 742-750, 2017 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28281183
13.
Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma.
Haematologica;
102(12): 2104-2112, 2017 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28971900
14.
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Lancet Oncol;
17(5): 622-31, 2016 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27049457
15.
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
Lancet Oncol;
16(3): 284-92, 2015 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25683846
16.
Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.
Br J Haematol;
168(5): 663-70, 2015 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25316653
17.
A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061.
Cancer;
120(8): 1194-202, 2014 Apr 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24474568
18.
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.
Blood;
119(7): 1665-70, 2012 Feb 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22184409
19.
A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies.
Invest New Drugs;
31(2): 355-62, 2013 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22615058
20.
Augmenting advance care planning in poor prognosis cancer with a video decision aid: a preintervention-postintervention study.
Cancer;
118(17): 4331-8, 2012 Sep 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22252775